M. Hannula

Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases

J. Tenorio-Laranga, P. Männistö, J. Garcia-horsman, 2013, Neuroscience.

Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers

T. Myöhänen, M. Hannula, L. Dokleja, 2014, Neuroscience Letters.

Sequential Expression, Activity and Nuclear Localization of Prolyl Oligopeptidase Protein in the Developing Rat Brain

T. Myöhänen, M. Hannula, P. Männistö, 2010, Developmental Neuroscience.

PROLYL OLIGOPEPTIDASE IN DEVELOPMENT

M. Hannula, 2010 .

Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases

J. Tenorio-Laranga, T. Myöhänen, J. Garcia-horsman, 2013, Neuroscience.

A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

V. Baekelandt, A. Lambeir, R. Van Elzen, 2012, British journal of pharmacology.